Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.
Subscribe to see Innocras’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Innocras is a healthcare company headquartered in South Korea. Its most recent funding round, Series B3, raised $33.8M in August 2026.
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B3 | $33.8M | 11 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Innocras's closest competitors — see the full list of competitors and alternatives →
Inocras Inc. is a bioinformatics-led biotechnology company headquartered in San Diego, California. The firm utilizes whole genome data and proprietary artificial intelligence analytics to deliver curated genomic care.
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
4baseCare is an Illumina-backed company headquartered in Singapore, focused on developing cutting-edge Precision Oncology Solutions using Advanced Genomics. The company also provides free NGS-biomarker testing for eligible lung cancer patients across India.
Amoy Dx is a diagnostic company dedicated to transforming cancer care by breaking barriers in precision oncology. The company develops specialized genomic tools and diagnostics products, such as the AmoyDx Essential NGS Panel used in clinical trials. It operates as a visionary enterprise within the precision medicine and diagnostics sector.
Oncoliq is an Argentinian startup based in Buenos Aires that combines cutting-edge AI with molecular biology to develop an early cancer detection screening method using a liquid biopsy blood test.
Tempus AI, Inc. is an American health technology company founded in 2015 in Chicago, Illinois. The company builds a practical platform to gather and analyze clinical and molecular data, empowering physicians to make data-driven patient care decisions.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Innocras? Suggest a correction · Work at Innocras? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.